Salspera ^{Filed, US Offering, Nasdaq: TKVA}

Our company is focused on the development and commercialization of a new class of immunotherapeutics for the treatment of solid tumors. This new class of drugs, sometimes referred to as “live biopharmaceuticals” are genetically modified biological agents which have the capability of expressing select anti-tumoral agents within the tumor’s microenvironment. Our lead program, Saltikva, is an attenuated strain of Salmonella Typhimurium that is non-toxic and orally administered. This strain of Salmonella Typhimurium is engineered to express the human gene interleukin-2, or Salmonella-IL2. The natural activity of IL-2 is to increase populations of NK and CD8+ cytotoxic T cells in tumor microenvironments as well as in the peripheral blood. Both of these cell types have the unique property of indiscriminately killing cancer cells. Saltikva is being developed for the treatment of multiple oncology indications, including pancreatic cancer and osteosarcoma. We conducted a Phase 2 clinical trial in humans for Saltikva for Stage IV metastatic pancreatic cancer, where we observed lower tumor burden and increase Progression Free Survival (“PFS”) and Overall Survival (“OS”) in patients when administered in conjunction with modified chemotherapy, FOLFIRINOX. Our Company is entering into pivotal Phase 3 clinical trials for our Saltikva product in the treatment of Stage IV metastatic pancreatic cancer patients.